Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 11/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22893059 | 0.91 | TOP1 (0.63) | TOP1KDM4EGLAGAAHTT | |
| SCHEMBL21297667 | 0.89 | TOP1 (0.61) | TOP1KDM4EGLAGAAHTT | |
| SCHEMBL29321609 | 0.88 | TOP1 (0.56) | TOP1KDM4EGLAGAAHTT | |
| SCHEMBL26028082 | 0.87 | TOP1 (0.59) | TOP1KDM4EGLAGAAHTT | |
| SCHEMBL16491947 | 0.86 | TOP1 (0.82) | TOP1KDM4EGLAGAAHTT | |
| SCHEMBL22893063 | 0.84 | TOP1 (0.56) | TOP1KDM4EGLAGAAHTT | |
| SCHEMBL29321355 | 0.84 | TOP1 (0.58) | TOP1KDM4EGLAGAAHTT | |
| SCHEMBL21297696 | 0.84 | TOP1 (0.63) | TOP1KDM4EGLAGAAHTT | |
| SCHEMBL22843989 | 0.83 | TOP1 (0.65) | TOP1KDM4EGLAGAAHTT | |
| SCHEMBL26028154 | 0.83 | TOP1 (0.65) | TOP1KDM4EGLAGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009719-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | Cybrexa 2, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-10391063-B2 | Pharmaceutical composition of polyethylene glycol-modified camptothecin derivative and preparation method thereof | JENKEM TECHNOLOGY CO., LTD. (TIANJIN) (CN) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009719-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | TOP1, TOP2A, TOP2B | TOP1 1/4885KDM4E 4298/4885GLA 2632/4885 |
| US-10391063-B2 | Pharmaceutical composition of polyethylene glycol-modified camptothecin derivative and preparation method thereof | LPXN, PDE10A, PDE8A | TOP1 5/4885KDM4E 4632/4885GLA 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.